Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018;38(3):443-450.

Publication Type:

Journal Article

Authors:

Asselah, Tarik; Bourgeois, Stefan; Pianko, Stephen; Zeuzem, Stefan; Sulkowski, Mark; Foster, Graham R.; Han, Lingling; McNally, John; Osinusi, Anu; Brainard, Diana M.; Subramanian, G. Mani; Gane, Edward J.; Feld, Jordan J.; Mangia, Alessandra

Source:

Liver Int, Volume 38, Issue 3, p.443-450 (2018)

Keywords:

Antiviral Agents, Direct-acting antivirals, NS5A inhibitor, Polymerase inhibitor

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/28756625

Export Citation:

RIS Format

Top